The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution?

Eur J Cancer. 2011 Jun;47(9):1285-6. doi: 10.1016/j.ejca.2011.04.002. Epub 2011 May 5.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Cost-Benefit Analysis
  • Drug Costs*
  • Drug Industry / economics
  • Drug Industry / trends
  • Economics, Pharmaceutical
  • European Union
  • Health Care Rationing
  • Humans
  • Medicare Part D
  • Models, Economic
  • Neoplasms / drug therapy*
  • United States